Xilio Therapeutics/$XLO
1D1W1M3M6MYTD1Y5YMAX
Capital at risk
About Xilio Therapeutics
Xilio Therapeutics Inc is a clinical-stage biotechnology company focused on discovering and developing masked immuno-oncology (I-O) therapies to improve outcomes for people living with cancer. Leveraging its clinically validated masking technology and capabilities, the company develops I-O therapies designed to selectively activate within the tumor microenvironment to achieve durable efficacy without the severe side effects associated with systemically active I-O agents. Its integrated biology and protein engineering approach enables the design and development of potent masked biologics that are activated by tumor-specific proteases.
- Ticker
- $XLO
- Sector
- Health
- Primary listing
- NASDAQ
- Employees
- 76
- Headquarters
- Waltham, United States
- Website
- xiliotx.com
XLO Metrics
BasicAdvanced
$56M
-
-$1.74
-
-
Price and volume
Market cap
$56M
52-week high
$9.90
52-week low
$6.68
Average daily volume
14K
Financial strength
Current ratio
4.72
Quick ratio
4.559
Long term debt to equity
0.066
Total debt to equity
0.087
Interest coverage (TTM)
-70.29%
Profitability
EBITDA (TTM)
-39.869
Gross margin (TTM)
168.93%
Net profit margin (TTM)
-20.89%
Operating margin (TTM)
-74.87%
Revenue per employee (TTM)
$720,000
Management effectiveness
Return on assets (TTM)
-19.17%
Return on equity (TTM)
-38.21%
Valuation
Price to revenue (TTM)
1.014
Price to book
0.82
Price to tangible book (TTM)
0.82
Price to free cash flow (TTM)
-0.968
Free cash flow yield (TTM)
-103.27%
Free cash flow per share (TTM)
-8.747
Growth
Revenue change (TTM)
72.97%
Earnings per share change (TTM)
-88.96%
3-year earnings per share growth (CAGR)
-65.21%
What the Analysts think about XLO
Analyst ratings (Buy, Hold, Sell) for Xilio Therapeutics stock.
Analyst projections of the future price of Xilio Therapeutics stock.
XLO Financial Performance
Revenues and expenses
XLO Earnings Performance
Company profitability
Upcoming events
No upcoming events
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.